Clinical Trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.
Protocol Amendment History 5 changes
notable Trial sites expanded: 287 -> 295 locations 2026-08-15
notable Enrollment increased: 878 -> 1160 participants 2026-07-15
notable Trial sites expanded: 283 -> 286 locations 2026-06-30
notable Primary completion pushed: 2029-05-10 -> 2030-11-18 2026-06-30
minor Completion pushed: 2030-03-25 -> 2030-11-18 2026-06-30
Trial Details
NCT Number NCT06627647
Lead Sponsor AstraZeneca
Conditions Non-squamous Non-small Cell Lung Cancer
Enrollment 1,160 participants
Start Date 2024-11-27
Primary Completion 2030-11-18 (estimated)
Study Completion 2030-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-14